Table 4. Complications, treatments and clinical outcomes.
| Variables | Total (n = 167) | Thrombocytopenia (n = 41) | Non-thrombocytopenia (n = 126) | P value |
|---|---|---|---|---|
| Treatments | ||||
| Antiviral therapy | 79 (47.31%) | 25 (60.98%) | 54 (42.86%) | 0.04 |
| Arbidol | 28 (16.77%) | 12 (29.27%) | 16 (12.70%) | 0.01 |
| Ribavirin | 19 (11.38%) | 6 (14.63%) | 13 (10.32%) | 0.57 |
| Entecavir | 1 (0.60%) | 1 (2.44%) | 0 | 0.25 |
| Interferon | 21 (12.57%) | 3 (7.32%) | 18 (14.29%) | 0.29 |
| Chloroquine phosphate | 3 (1.80%) | 1 (2.44%) | 2 (1.59%) | 0.57 |
| Antibiotic therapy | 154 (92.22%) | 38 (92.68%) | 116 (92.06%) | 0.90 |
| Imipenem/meropenem | 73 (43.71%) | 23 (31.5%) | 50 (39.68%) | 0.07 |
| Quinolone | 106 (63.47%) | 27 (65.85%) | 79 (62.70%) | 0.72 |
| Cephalosporin | 95 (56.89%) | 24 (58.54%) | 71 (56.35%) | 0.81 |
| Piperacillin sodium and sulbactam sodium | 23 (13.77%) | 3 (7.32%) | 20 (15.87%) | 0.17 |
| Azithromycin | 5 (2.99%) | 1 (2.44%) | 4 (3.17%) | 0.81 |
| Linezolid | 31 (18.56%) | 5 (12.20%) | 26 (20.63%) | 0.23 |
| Polymyxin B | 12 (7.19%) | 3 (7.32%) | 9 (7.14%) | 0.97 |
| Vancomycin | 20 (11.98%) | 6 (14.63%) | 14 (11.11%) | 0.55 |
| Daptomycin | 1 (0.60%) | 0 | 1 (0.79%) | 1.00 |
| Tigecycline | 17 (10.18%) | 4 (9.76%) | 13 (10.32%) | 1.00 |
| Antifungal therapy | 34 (20.36%) | 9 (21.95%) | 25 (19.84%) | 0.79 |
| Caspofungin | 12 (7.19%) | 4 (9.76%) | 8 (6.35%) | 0.46 |
| Fluconazole | 6 (3.59%) | 1 (2.44%) | 5 (3.97%) | 1.00 |
| Voriconazole | 13 (7.78%) | 3 (7.32%) | 10 (7.94%) | 1.00 |
| Immunomodulator | ||||
| Thymalfasin/ Thymosin | 21 (12.57%) | 4 (9.76%) | 17 (13.49%) | 0.53 |
| XUE BI JING injection | 20 (11.98%) | 8 (19.51%) | 12 (9.52%) | 0.09 |
| Ulinastatin | 6 (3.59%) | 2 (4.88%) | 4 (3.17%) | 0.64 |
| Corticosteroids therapy | 73 (43.71%) | 21 (51.22%) | 52 (41.27%) | 0.27 |
| Respiratory support | ||||
| High-flow oxygen therapy | 63 (37.72%) | 14 (34.15%) | 49 (38.89%) | 0.59 |
| Non-invasive ventilation | 59 (35.33%) | 16 (39.02%) | 43 (34.13%) | 0.57 |
| Invasive ventilation | 75 (44.91%) | 24 (58.54%) | 51 (40.48%) | 0.04 |
| Duration of invasive ventilation, days | 11.00 [6.00–20.00] | 12.00 [7.00–22.00] | 8.50 [5.00–13.00] | 0.08 |
| Vasopressors | 70 (41.92%) | 22 (53.66%) | 48 (38.10%) | 0.08 |
| CRRT | 34 (20.40%) | 8 (19.50%) | 26 (20.60%) | 0.88 |
| ECMO | 21 (12.60%) | 4 (9.80%) | 17 (13.50%) | 0.53 |
| Complications | ||||
| Secondary infections | 98 (57.68%) | 21 (51.22%) | 77 (61.11%) | 0.26 |
| Septic shock | 48 (28.74%) | 17 (41.46%) | 31 (24.60%) | 0.04 |
| ARDS | 148 (88.62%) | 38 (92.68%) | 110 (87.30%) | 0.35 |
| Acute kidney injury | 34 (20.48%) | 11 (26.83%) | 23 (18.40%) | 0.25 |
| Arrhythmia | 35 (20.96%) | 17 (41.46%) | 18 (14.29%) | <0.01 |
| Acute cardiac injury | 57 (34.13%) | 19 (46.34%) | 38 (30.16%) | 0.06 |
| Coagulation disorder | 43 (25.75%) | 18 (43.90%) | 25 (19.84%) | <0.01 |
| Main outcomes | ||||
| ICU length of stay, days | 12.00 [7.00–21.00] | 10.50 [5.50–15.75] | 13.00 [8.00–23.00] | 0.03 |
| Hospital length of stay, days | 21.00 [15.00–35.00] | 20.00 [11.00–26.50] | 23.00 [15.75–36.25] | 0.06 |
| 28-day mortality | 58 (34.73%) | 23 (56.10%) | 35 (27.78%) | <0.01 |
| 90-day mortality | 84 (50.29%) | 27 (65.85%) | 57 (45.24%) | 0.02 |
| 180-day mortality | 87 (52.1%) | 27 (65.85%) | 60 (47.62%) | 0.04 |
| Survival prognosis in 180 days | ||||
| Survival, numbers | 80 | 14 | 66 | |
| Extra oxygen supply | 14 (17.50%) | 5 (35.71%) | 9 (13.64%) | 0.06 |
| Exertional dyspnea | 17 (21.25%) | 3 (21.43%) | 14 (21.21%) | 1.00 |
| weakness | 15 (18.75%) | 3 (21.43%) | 12 (18.18%)) | 0.72 |
(SD) standard deviation; (IQR) Inter quartile range; (SOFA) Sequential Organ Failure Assessment; (CRRT) continuous renal replacement therapy; (ECMO), extracorporeal membrane oxygenation; (ARDS) acute respiratory distress syndrome.